{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:15:04Z","timestamp":1771661704299,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T00:00:00Z","timestamp":1344470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s10067-012-2040-2","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T06:19:26Z","timestamp":1344406766000},"page":"1281-1287","source":"Crossref","is-referenced-by-count":12,"title":["The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what\u2019s in it for African and Middle Eastern rheumatologists"],"prefix":"10.1007","volume":"31","author":[{"given":"Adel","family":"Alawadhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldoon","family":"Alawneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad Ahmed","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,9]]},"reference":[{"key":"2040_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","volume":"21","author":"GJ Wolbink","year":"2009","unstructured":"Wolbink GJ, Aarden LA, Dijkmans BA (2009) Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 21:211\u2013215","journal-title":"Curr Opin Rheumatol"},{"key":"2040_CR2","unstructured":"EU summary of product characteristics: Remicade (2012) Centocor BV, Leiden"},{"key":"2040_CR3","unstructured":"EU summary of product characteristics: Humira (2012) Abbott Biotechnology Deutschland GmBH, Wiesbaden"},{"key":"2040_CR4","unstructured":"Prescribing information: Rituximab (2012). Biogen Idec Inc and Genentech, South San Francisco"},{"key":"2040_CR5","unstructured":"EU summary of product characteristics: Enbrel (2012) Pfizer, Hampshire"},{"key":"2040_CR6","unstructured":"EU summary of product characteristics: Cimzia (2011) UCB Pharma, Bruselles"},{"key":"2040_CR7","unstructured":"EU summary of product characteristics: MabThera (2012) Roche Pharma AG, Grenzach-Wyhlen"},{"key":"2040_CR8","unstructured":"EU summary of prescribing characteristics: Simponi (2012) Centocor BV, Leiden"},{"key":"2040_CR9","unstructured":"EU summary of product characteristics: RoActemra (2011) Roche Registration, Welwyn Garden City"},{"key":"2040_CR10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916","journal-title":"N Engl J Med"},{"issue":"2 Suppl 1","key":"2040_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","volume":"22","author":"TK Kvien","year":"2004","unstructured":"Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):1\u201312","journal-title":"Pharmacoeconomics"},{"key":"2040_CR12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10067-007-0782-z","volume":"27","author":"H Badsha","year":"2008","unstructured":"Badsha H, Kong KO, Tak PP (2008) Rheumatoid arthritis in the United Arab Emirates. Clin Rheumatol 27:739\u2013742","journal-title":"Clin Rheumatol"},{"key":"2040_CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.berh.2008.04.003","volume":"22","author":"GM Mody","year":"2008","unstructured":"Mody GM, Cardiel MH (2008) Challenges in management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 22:621\u2013641","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2040_CR14","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","volume":"24","author":"H Schellekens","year":"2002","unstructured":"Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720\u20131740","journal-title":"Clin Ther"},{"key":"2040_CR15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"N Emi Aikawa","year":"2010","unstructured":"Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E (2010) Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82\u201389","journal-title":"Clin Rev Allergy Immunol"},{"key":"2040_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WY Hwang","year":"2005","unstructured":"Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3\u201310","journal-title":"Methods"},{"key":"2040_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbt.2009.03.012","volume":"25","author":"EM Jahn","year":"2009","unstructured":"Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic protiens-regulatory considerations. N Biotechnol 25:280\u2013286","journal-title":"N Biotechnol"},{"issue":"5 Suppl 1","key":"2040_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","volume":"34","author":"PJ Anderson","year":"2005","unstructured":"Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl 1):19\u201322","journal-title":"Semin Arthritis Rheum"},{"key":"2040_CR19","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739\u20131745","journal-title":"Ann Rheum Dis"},{"key":"2040_CR20","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460\u20131468","journal-title":"JAMA"},{"key":"2040_CR21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"N Emi Aikawa","year":"2010","unstructured":"Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonf\u00e1 E (2010) Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82\u201389","journal-title":"Clin Rev Allergy Immunol"},{"key":"2040_CR22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/mi.3.6.310","volume":"6","author":"R Fleischmann","year":"2003","unstructured":"Fleischmann R, Shealy D (2003) Developing a new generation of TNF alpha antagonists for the treatment of rheumatoid arthritis. Mol Interv 6:310\u2013318","journal-title":"Mol Interv"},{"key":"2040_CR23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711\u2013715","journal-title":"Arthritis Rheum"},{"key":"2040_CR24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"2040_CR25","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK Vries de","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SQ, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66:1252\u20131254","journal-title":"Ann Rheum Dis"},{"key":"2040_CR26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921\u2013926","journal-title":"Ann Rheum Dis"},{"key":"2040_CR27","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends S, Lebbink HR, Spoorenberg et al (2010) The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28:661\u2013668","journal-title":"Clin Exp Rheumatol"},{"key":"2040_CR28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld RC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131563","journal-title":"Arthritis Rheum"},{"key":"2040_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353\u2013363","journal-title":"Arthritis Rheum"},{"key":"2040_CR30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","volume":"68","author":"MK Vries de","year":"2009","unstructured":"de Vries MK, van der Horst-Bruinsma IE et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531\u2013535","journal-title":"Ann Rheum Dis"},{"key":"2040_CR31","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11(Supp 11): S1","DOI":"10.1186\/ar2666"},{"key":"2040_CR32","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29","journal-title":"Arthritis Res Ther"},{"key":"2040_CR33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13\u201320","journal-title":"Arthritis Rheum"},{"key":"2040_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","volume":"66","author":"F Iannone","year":"2007","unstructured":"Iannone F, Trotta F, Montecucco C et al (2007) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66:249\u2013252","journal-title":"Ann Rheum Dis"},{"key":"2040_CR35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","volume":"70","author":"A Jamnitski","year":"2011","unstructured":"Jamnitski A, Bartelds GM, Nurmohamed MT et al (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284\u2013288","journal-title":"Ann Rheum Dis"},{"key":"2040_CR36","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/ard.2008.098467","volume":"68","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856\u20131862","journal-title":"Ann Rheum Dis"},{"key":"2040_CR37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Goria R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 1173:837\u2013846","journal-title":"Ann NY Acad Sci"},{"key":"2040_CR38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22\u201332","journal-title":"Arthritis Rheum"},{"key":"2040_CR39","first-page":"26","volume":"29","author":"RJ Moots","year":"2011","unstructured":"Moots RJ, Haraoui B, Matacci-Cerinic M et al (2011) Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 29:26\u201334","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2040-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-012-2040-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2040-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T16:25:10Z","timestamp":1562084710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-012-2040-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["2040"],"URL":"https:\/\/doi.org\/10.1007\/s10067-012-2040-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}